Orexo

Declaration of Voting Results & Voting Rights Announcements • Jul 31, 2015

Press release

Number of shares and votes in Orexo

Uppsala, Sweden – July 31, 2015 – The number of shares and votes in Orexo AB have changed as a result of that the company has repurchased the entire issue of class C shares.

Today, the last trading day of the month, there are in total 34,580,810 shares - whereof 34,445,810 are ordinary shares and 135,000 class C shares - and 34,459,310 votes in the company.

For further information, please contact: Henrik Juuel, EVP and Chief Financial Officer Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.

For information about Orexo please visit www.orexo.com